Tango Therapeutics (TNGX)
(Real Time Quote from BATS)
$7.89 USD
+0.27 (3.54%)
Updated Sep 18, 2025 01:08 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TNGX 7.89 +0.27(3.54%)
Will TNGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TNGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNGX
Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock?
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates
TNGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade
Other News for TNGX
Expansion Breakout appears for TNGX after 3.67% move
Major Stakeholder Sells Off Tango Therapeutics Shares in Multi-Million Dollar Deal
TNGX forms 20 Day Moving Average Support on September 16
Is TNGX building bullish momentum? Crossed Above 20 Day Moving Average shows up after advancing 4.44%
TNGX Fell Below 20 Day Moving Average on September 12